🇺🇸 FDA
Patent

US 8790652

Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis

granted A61KA61K2039/507A61K39/3955

Quick answer

US patent 8790652 (Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis) held by VACCINEX, INC. expires Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VACCINEX, INC.
Grant date
Tue Jul 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K2039/507, A61K39/3955